{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:43:33Z","timestamp":1792755813499,"version":"4.5.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background and Aim:<\/jats:bold> Non-alcoholic fatty liver (NAFLD) is one of the most common progressive metabolic disorders worldwide. There are increasing scientific interests nowadays for the association between vitamin D status and Non-alcoholic fatty liver. Earlier studies have revealed that vitamin D deficiency is highly prevalent in Non-alcoholic fatty liver patients that contributes to poor outcomes. Hence, the present study aimed to assess the efficacy and safety of oral cholecalciferol on Non-alcoholic fatty liver patients.<\/jats:p><jats:p><jats:bold>Subjects and Methods:<\/jats:bold> This study was conducted on 140 patients that were randomized either to group 1 that received the standard conventional therapy in addition to placebo or group 2 that received the standard conventional therapy in addition to cholecalciferol during the 4 months study period.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> At the end of the study group 2 revealed significant decrease (<jats:italic>p<\/jats:italic> &amp;lt; 0.05) in the mean serum level of TG, LDL-C, TC, hsCRP as compared to their baseline results and group 1 results. Additionally, a significant improvement in the serum levels of ALT (<jats:italic>p<\/jats:italic> = 0.001) was seen in group 2 at the end of the study when compared to group 1. Whereas group 1 did not show any change in these parameters when compared to group 2 and their baseline results.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Cholecalciferol was shown to have beneficial effects on serum ALT levels, hsCRP levels and lipid profile of NAFLD patients.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>https:\/\/prsinfo.clinicaltrials.gov\/prs-users-guide.html<\/jats:ext-link>, identifier NCT05613192<\/jats:p>","DOI":"10.3389\/fphar.2023.1149967","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T04:23:40Z","timestamp":1678767820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Amal Ahmed","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Abdel","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seham Mohamed","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Mohamed","family":"Bahgat Eldemiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha Sobh","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Maamoun","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina G.","family":"Naguib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwa M.","family":"Muharram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona G.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Saed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Salah Seif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Nasraldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Elsaid","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwa","family":"El Borolossy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1136\/gut.2010.234666","article-title":"Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats","volume":"60","author":"Abramovitch","year":"2011","journal-title":"Gut"},{"key":"B2","doi-asserted-by":"publisher","first-page":"G112","DOI":"10.1152\/ajpgi.00132.2013","article-title":"Vitamin D inhibits development of liver fibrosis in an animal model but cannot ameliorate established cirrhosis","volume":"308","author":"Abramovitch","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.7869\/tg.219","article-title":"Nonalcoholic fatty liver disease \u2013 The clinician\u2019s perspective","volume":"35","author":"Agrawal","year":"2014","journal-title":"Trop. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc09-s013","article-title":"Standards of medical care in diabetes\u20142009","volume":"32","year":"2022","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1741-7015-9-85","article-title":"Strong association between nonalcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes","volume":"9","author":"Barchetta","year":"2011","journal-title":"BMC Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1002\/hep.25930","article-title":"Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: Relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus","volume":"56","author":"Barchetta","year":"2012","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/nu9091015","article-title":"Vitamin D supplementation and non-alcoholic fatty liver disease: Present and future","volume":"9","author":"Barchetta","year":"2017","journal-title":"Nutrients"},{"key":"B8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12916-016-0638-y","article-title":"No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial","volume":"14","author":"Barchetta","year":"2016","journal-title":"BMC Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/gutjnl-2014-307024","article-title":"Vitamin D counteracts fibrogenic TGF-\u03b2 signalling in human hepatic stellate cells both receptor-dependently and independently","volume":"64","author":"Beilfuss","year":"2015","journal-title":"Gut"},{"key":"B10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: An expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1053\/j.gastro.2011.06.061","article-title":"Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States","volume":"141","author":"Charlton","year":"2011","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"8341","DOI":"10.3748\/wjg.v20.i26.8341","article-title":"Modern approach to the clinical management of non-alcoholic fatty liver disease","volume":"20","author":"Del Ben","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cell.2013.03.028","article-title":"A Vitamin D receptor\/SMAD genomic circuit gates hepatic fibrotic response","volume":"153","author":"Ding","year":"2013","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/apt.12377","article-title":"Meta-analysis: vitamin D and non-alcoholic fatty liver disease","volume":"38","author":"Eliades","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"59","year":"2016","journal-title":"Diabetologia"},{"key":"B17","first-page":"205","article-title":"Is visceral fat reduction necessary to favour metabolic changes in the liver?","volume":"21","author":"Finelli","year":"2012","journal-title":"J. Gastrointestin Liver Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/1735-9066.174759","article-title":"The effect of Vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"21","author":"Foroughi","year":"2016","journal-title":"Iran. J. Nurs. Midwifery Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr. Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jhep.2010.12.026","article-title":"Shedding new light on vitamin D and fatty liver disease","volume":"55","author":"Geier","year":"2011","journal-title":"J. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J. hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1097\/MD.0000000000016018","article-title":"The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease an observational Study","volume":"98","author":"Kim","year":"2019","journal-title":"Medicine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/gutjnl-2015-310417","article-title":"High-dose vitamin D supplementation and liver histology in NASH","volume":"65","author":"Kitson","year":"2016","journal-title":"Gut"},{"key":"B24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jhep.2005.11.030","article-title":"Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?","volume":"44","author":"Larter","year":"2006","journal-title":"J. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3177\/jnsv.65.303","article-title":"Association between vitamin D status and nonalcoholic fatty liver disease: A population-based study","volume":"65","author":"Liu","year":"2019","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/17512433.2017.1365599","article-title":"The pharmacological management of NAFLD in children and adolescents","volume":"21","author":"Liyanagedera","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.clnu.2016.09.020","article-title":"Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial","volume":"36","author":"Lorvand Amiri","year":"2017","journal-title":"Clin. Nutr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12891-016-1174-9","article-title":"An initial loading-dose vitamin D versus placebo after hip fracture surgery: Randomized trial","volume":"17","author":"Mak","year":"2016","journal-title":"BMC Musculoskelet. Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/hep.23724","article-title":"Low levels of 25-hydroxyvitamin D (3) in children with biopsy-proven nonalcoholic fatty liver disease","volume":"51","author":"Manco","year":"2010","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/nu5010111","article-title":"Vitamin D-effects on skeletal and extraskeletal health and the need for supplementation","volume":"5","author":"Matthias","year":"2013","journal-title":"Nutrients"},{"key":"B31","doi-asserted-by":"publisher","first-page":"154925","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism"},{"key":"B32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1530\/EJE-13-0609","article-title":"Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease","volume":"170","author":"Nobili","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.20524\/aog.2018.0240","article-title":"Non-alcoholic fatty liver disease: Controlling an emerging epidemic, challenges, and future directions","volume":"31","author":"Ofosu","year":"2018","journal-title":"Ann. Gastroenterol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/1389557518666181025153712","article-title":"Association between vitamin D levels and nonalcoholic fatty liver disease: Potential confounding variables","volume":"19","author":"Pacifico","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3899\/jrheum.120536","article-title":"Superiority of a high loading dose of cholecalciferol to correct hypovitaminosis D in patients with inflammatory\/autoimmune rheumatic diseases","volume":"40","author":"Sainaghi","year":"2013","journal-title":"J. Rheumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jgh3.12010","article-title":"Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial","volume":"1","author":"Sakpal","year":"2017","journal-title":"J. Gastroen Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12020-014-0336-5","article-title":"Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial","volume":"47","author":"Sharifi","year":"2014","journal-title":"Endocrine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.numecd.2006.04.002","article-title":"Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease","volume":"17","author":"Targher","year":"2007","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2337\/dc06-1539","article-title":"Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease","volume":"30","author":"Tolman","year":"2007","journal-title":"Diabetes Care"},{"key":"B40","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1017\/S0007114516000386","article-title":"Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: A cross-sectional study (survey on prevalence in East China for metabolic diseases and risk factors (spect-China))","volume":"115","author":"Zhai","year":"2016","journal-title":"Br. J. Nutr."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1149967\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T04:23:43Z","timestamp":1678767823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1149967\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":42,"alternative-id":["10.3389\/fphar.2023.1149967"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1149967","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"article-number":"1149967"}}